Beacon Pointe Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Beacon Pointe Advisors's REGN Position: Q2 2026 in Review
Beacon Pointe Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 19,460 shares worth $12.1M. The position accounts for 0.06% of the portfolio, ranked #295.
Beacon Pointe Advisors first reported a position in REGN in Q2 2021 and has held it in 21 quarters since. The position peaked at $23.4M in Q2 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Beacon Pointe Advisors held 19,460 shares of Regeneron Pharmaceuticals worth $12.1M as of Q2 2026.
- Beacon Pointe Advisors left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
- Regeneron Pharmaceuticals made up 0.06% of Beacon Pointe Advisors's portfolio in Q2 2026, its #295 holding.
- Beacon Pointe Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
- Beacon Pointe Advisors's Regeneron Pharmaceuticals position peaked at $23.4M in Q2 2024.
- 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.